Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBX-2982 for Glucagon Counter-regulation in Type 1 Diabetes
NCT04432090Phase 2Completed
- Sponsor
- AdventHealth Translational Research Institute
- Start
- Apr 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mbx-2982 in type 1 diabetes mellitus (T1D), sponsored by AdventHealth Translational Research Institute. Started Apr 2021; status: completed.
02
Drugs
mbx-2982
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04432090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04432090.